Milestone Achievement Signals Company's Commitment to Solidifying its Leadership in the Australian Market

里程碑式的成就表明公司致力于巩固其在澳大利亚市场的领导地位

NASDAQ | TSX: ACB

纳斯达克证券交易所：ACB

EDMONTON, AB, March 20, 2024 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) – The Canadian based leading global medical cannabis company has received Good Manufacturing Practice (GMP) certification from Australia's Therapeutic Goods Administration (TGA) for its Canadian production facilities, River and Ridge.

艾德蒙顿，AB，2024年3月20日/PRNewswire/-Aurora大麻公司（纳斯达克股票代码：ACB）（TSX股票代码：ACB）-这家总部位于加拿大的领先全球医用大麻公司已获得澳大利亚治疗用品管理局（TGA）对其加拿大生产设施River and Ridge的良好生产规范（GMP）认证。

The TGA is responsible for regulating the supply, import, export, manufacturing and advertising of therapeutic goods in Australia.  Obtaining TGA's GMP certification enables the company to deliver top-tier cannabis products to Australia while confirming Aurora's dedication to exporting products fully compliant with TGA regulations and the stipulations of TGO 93 (Standard for Medical Cannabis).

TGA负责管理澳大利亚治疗用品的供应、进口、出口、制造和广告。获得TGA的GMP认证使该公司能够向澳大利亚提供顶级大麻产品，同时确认Aurora致力于出口完全符合TGA法规和TGO 93（医用大麻标准）规定的产品。

The license grants approval for Aurora to broaden its product range offerings in the country, comprising dried flower, resin cartridges, pastilles and oils..

该许可证批准Aurora扩大其在该国的产品范围，包括干花、树脂盒、锭剂和油。。

'I'm proud to announce Aurora has obtained TGA GMP certification for our world class Canadian production facilities,' said Gorana Lakic, Vice President, Quality at Aurora. 'This achievement adds to the number of global certifications Aurora has received and solidifies our dedication to quality and compliance.

Aurora质量副总裁GoranaLakic说，我很骄傲地宣布Aurora已经获得了加拿大世界级生产设施的TGA GMP认证这一成就增加了Aurora获得的全球认证数量，巩固了我们对质量和合规性的承诺。

With this significant achievement, we reaffirm our commitment to maintaining the highest standards and manufacturing practices to deliver premium medical cannabis products to our valued patients.'.

凭借这一重大成就，我们重申致力于保持最高标准和生产实践，为我们尊贵的患者提供优质医用大麻产品。”。

This landmark certification, granted on March 15, 2024, strengthens Aurora's dedication to supporting the continued growth and development of the Australian medical cannabis market, which is rapidly expanding and estimated to be worth $400 million AUD, making it the largest medical market in the world outside of North America.1 As the long-standing exclusive supplier to MedReleaf Australia, and recently announced parent company, Aurora will continue to introduce innovative and differentiated products to the market..

这一里程碑式的认证于2024年3月15日授予，加强了Aurora致力于支持澳大利亚医用大麻市场的持续增长和发展，该市场正在迅速扩张，估计价值4亿澳元，使其成为北美以外世界上最大的医疗市场。1作为MedReleaf Australia的长期独家供应商，以及最近宣布的母公司，Aurora将继续向市场推出创新和差异化产品。。

MedReleaf Australia and Aurora remain dedicated to ensuring Australian patients can access a dependable and consistent supply of premium-quality products and providing doctors expanded options for patient care.

MedReleaf Australia和Aurora仍然致力于确保澳大利亚患者能够获得可靠且持续的优质产品供应，并为医生提供更多的患者护理选择。

For further information about medical cannabis products, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: www.medreleafaustralia.com.au.

有关医用大麻产品的更多信息，医生和医疗保健专业人员可以联系MedReleaf澳大利亚临床支持团队或访问他们的网站：www.medReleafaAustralia.com.au。

_________________________________

_________________________________

1 The Pennington Institute, 'Cannabis in Australia 2023.'  (Estimated revenue of AUD$210m for January to June 2023 has been annualized)

1彭宁顿研究所，“2023年澳大利亚大麻”（2023年1月至6月的估计收入为2.1亿澳元）

About Aurora Cannabis

关于Aurora大麻

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and South America. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult- use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard.

Aurora正在向世界开放大麻，服务于加拿大、欧洲、澳大利亚和南美洲的医疗和消费市场。Aurora总部位于艾伯塔省埃德蒙顿，是全球大麻的先驱，致力于帮助人们改善生活。该公司的成人品牌组合包括Drift、San Rafael’71、Daily Special、Tasty’s、Being和Greybeard。

Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched.

医用大麻品牌包括MedReleaf、CanniMed、Aurora和Whistler医用大麻公司，以及国际品牌Pedanios、Bidiol、IndiMed和CraftPlant。Aurora还拥有Bevo Farms Ltd.的控股权，Bevo Farms Ltd是北美领先的繁殖农业植物供应商。在科学和创新的推动下，Aurora的品牌以高质量大麻产品为重点，在医疗、保健和成人娱乐市场（无论在何处推出）继续取得行业领先地位。

Learn more at www.auroramj.com and follow us on X and LinkedIn. .

请访问www.auroramj.com了解更多信息，并在X和LinkedIn上关注我们。。

Aurora's Common Shares trade on the NASDAQ and TSX under the symbol 'ACB' and is a constituent of the S&P/TSX Composite Index.

Aurora的普通股在纳斯达克和多伦多证券交易所交易，股票代码为“ACB”，是标准普尔/多伦多证券交易所综合指数的组成部分。

Forward Looking Information

前瞻性信息

This news release includes statements containing certain 'forward-looking information' within the meaning of applicable securities law ('forward-looking statements'). Forward-looking statements are frequently characterized by words such as 'plan', 'continue', 'expect', 'project', 'intend', 'believe', 'anticipate', 'estimate', 'may', 'will', 'potential', 'proposed' and other similar words, or statements that certain events or conditions 'may' or 'will' occur.

本新闻稿包括包含适用证券法意义下的某些“前瞻性信息”的声明（“前瞻性声明”）。前瞻性陈述的特点通常是“计划”、“继续”、“期望”、“项目”、“打算”、“相信”、“预期”、“估计”、“可能”、“将会”、“潜在”、“提议”和其他类似词语，或者陈述某些事件或条件“可能”或“将”发生。

Forward-looking statements made in this news release include statements regarding the Company's continued dedication to the growth and development of the Australian medical cannabis market and to exporting products fully compliant with TGA regulations and the stipulations of TGO 93, the Company's continued expansion of the Company's product range offerings in Australia, and expectations for the size of the Australian medical cannabis market..

本新闻稿中发表的前瞻性声明包括，公司继续致力于澳大利亚医用大麻市场的增长和发展，出口完全符合TGA法规和TGO 93规定的产品，公司继续扩大公司在澳大利亚的产品范围，以及对澳大利亚医用大麻市场规模的预期。。

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable.

这些前瞻性声明只是预测。本新闻稿中包含的前瞻性信息或声明是根据管理层认为合理的假设编制的。制定前瞻性陈述所涉及的重大因素或假设包括但不限于来自政府来源、市场研究和行业分析的公开信息，以及基于本公司认为合理的行业数据和知识的假设。

Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements.

前瞻性陈述受到各种风险、不确定性和管理层认为在这种情况下相关且合理的其他因素的影响，这些因素可能导致实际事件、结果、活动水平、绩效、前景、机会或成就与前瞻性陈述中预测的大不相同。

These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield f.

这些风险包括但不限于留住关键人员的能力，继续投资基础设施以支持增长的能力，以可接受的条款获得融资的能力，我们产品的持续质量，客户体验和保留，第三方政府和非政府消费者销售渠道的发展，管理层对加拿大和公司出口辖区消费者需求的估计，对未来业绩和费用的预期，收购业务和运营成功整合的风险（就交易而言，更一般地说是就未来收购而言），管理层估计SG＆A只会随着收入增长的比例而增长，扩大和维持分销能力的能力，竞争的影响，金融市场的一般影响条件，产量f。

SOURCE Aurora Cannabis Inc.

来源Aurora大麻公司。